Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 4/20 | 0.48 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211110 | 0.86 | FFAR1 (0.53) | MAOBFFAR1KMT2ASMN1; SMN2BCHE | |
| SCHEMBL22724743 | 0.86 | SMN1; SMN2 (0.49) | MAOBFFAR1KMT2ASMN1; SMN2BCHE | |
| SCHEMBL22717572 | 0.86 | FFAR1 (0.53) | MAOBFFAR1KMT2ASMN1; SMN2BCHE | |
| SCHEMBL24646025 | 0.86 | SMN1; SMN2 (0.49) | MAOBFFAR1KMT2ASMN1; SMN2BCHE | |
| SCHEMBL29454548 | 0.86 | SMN1; SMN2 (0.49) | MAOBFFAR1KMT2ASMN1; SMN2BCHE | |
| SCHEMBL28969185 | 0.86 | FFAR1 (0.53) | MAOBFFAR1KMT2ASMN1; SMN2BCHE | |
| SCHEMBL20103390 | 0.84 | FFAR1 (0.46) | MAOBFFAR1KMT2ASMN1; SMN2BCHE | |
| SCHEMBL23923967 | 0.83 | BCHE (0.53) | MAOBFFAR1KMT2ASMN1; SMN2BCHE | |
| SCHEMBL23923970 | 0.83 | BCHE (0.53) | MAOBFFAR1KMT2ASMN1; SMN2BCHE | |
| SCHEMBL30317816 | 0.83 | BCHE (0.53) | MAOBFFAR1KMT2ASMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20220289772-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289772-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | MAOB 2716/4885FFAR1 10/4885KMT2A 1750/4885 |
| US-20230151037-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | MAOB 2716/4885FFAR1 10/4885KMT2A 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.